470 related articles for article (PubMed ID: 25885224)
1. Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma.
Muro Y; Hosono Y; Sugiura K; Ogawa Y; Mimori T; Akiyama M
Arthritis Res Ther; 2015 Mar; 17(1):57. PubMed ID: 25885224
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen.
Mahler M; Raijmakers R; Dähnrich C; Blüthner M; Fritzler MJ
Arthritis Res Ther; 2005; 7(3):R704-13. PubMed ID: 15899056
[TBL] [Abstract][Full Text] [Related]
3. Anti-PM/Scl-100 and anti-RNA-polymerase III antibodies in scleroderma.
Maes L; Blockmans D; Verschueren P; Westhovens R; De Beéck KO; Vermeersch P; Van den Bergh K; Burlingame RW; Mahler M; Bossuyt X
Clin Chim Acta; 2010 Jul; 411(13-14):965-71. PubMed ID: 20346932
[TBL] [Abstract][Full Text] [Related]
4. PM1-Alpha ELISA: the assay of choice for the detection of anti-PM/Scl autoantibodies?
Mahler M; Fritzler MJ
Autoimmun Rev; 2009 Mar; 8(5):373-8. PubMed ID: 19103309
[TBL] [Abstract][Full Text] [Related]
5. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights.
Mahler M; Raijmakers R
Autoimmun Rev; 2007 Aug; 6(7):432-7. PubMed ID: 17643929
[TBL] [Abstract][Full Text] [Related]
6. Anti-PM/Scl autoantibodies in patients without clinical polymyositis or scleroderma.
Schnitz W; Taylor-Albert E; Targoff IN; Reichlin M; Scofield RH
J Rheumatol; 1996 Oct; 23(10):1729-33. PubMed ID: 8895149
[TBL] [Abstract][Full Text] [Related]
7. Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients.
D'Aoust J; Hudson M; Tatibouet S; Wick J; ; Mahler M; Baron M; Fritzler MJ
Arthritis Rheumatol; 2014 Jun; 66(6):1608-15. PubMed ID: 24577935
[TBL] [Abstract][Full Text] [Related]
8. Serological and clinical characterization of anti-dsDNA and anti-PM/Scl double-positive patients.
Mahler M; Greidinger EL; Szmyrka M; Kromminga A; Fritzler MJ
Ann N Y Acad Sci; 2007 Aug; 1109():311-21. PubMed ID: 17785320
[TBL] [Abstract][Full Text] [Related]
9. A Japanese patient with anti-PM/Scl and centromere antibody-positive scleroderma-amyopathic dermatomyositis overlap syndrome who developed renal crisis.
Nishida T; Nakano K; Satoh M; Fukuyo S; Akashi K; Tanaka Y
Mod Rheumatol Case Rep; 2022 Jan; 6(1):69-74. PubMed ID: 34506625
[TBL] [Abstract][Full Text] [Related]
10. The prevalence and significance of anti-PM/Scl antibodies in systemic sclerosis.
Wielosz E; Dryglewska M; Majdan M
Ann Agric Environ Med; 2021 Mar; 28(1):189-192. PubMed ID: 33775087
[TBL] [Abstract][Full Text] [Related]
11. Clinical performance evaluation of a novel rapid response chemiluminescent immunoassay for the detection of autoantibodies to extractable nuclear antigens.
Bentow C; Swart A; Wu J; Seaman A; Manfredi M; Infantino M; Benucci M; Lakos G; Mahler M
Clin Chim Acta; 2013 Sep; 424():141-7. PubMed ID: 23727029
[TBL] [Abstract][Full Text] [Related]
12. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients.
Hanke K; Brückner CS; Dähnrich C; Huscher D; Komorowski L; Meyer W; Janssen A; Backhaus M; Becker M; Kill A; Egerer K; Burmester GR; Hiepe F; Schlumberger W; Riemekasten G
Arthritis Res Ther; 2009; 11(1):R22. PubMed ID: 19220911
[TBL] [Abstract][Full Text] [Related]
13. C1D is a major autoantibody target in patients with the polymyositis-scleroderma overlap syndrome.
Schilders G; Egberts WV; Raijmakers R; Pruijn GJ
Arthritis Rheum; 2007 Jul; 56(7):2449-54. PubMed ID: 17599775
[TBL] [Abstract][Full Text] [Related]
14. Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients.
Franceschini F; Cavazzana I; Generali D; Quinzanini M; Viardi L; Ghirardello A; Doria A; Cattaneo R
J Rheumatol; 2002 Jul; 29(7):1393-7. PubMed ID: 12136894
[TBL] [Abstract][Full Text] [Related]
15. Anti-PM-Scl antibody in patients with systemic sclerosis.
Koschik RW; Fertig N; Lucas MR; Domsic RT; Medsger TA
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S12-6. PubMed ID: 22261302
[TBL] [Abstract][Full Text] [Related]
16. PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome.
Raijmakers R; Renz M; Wiemann C; Egberts WV; Seelig HP; van Venrooij WJ; Pruijn GJ
Arthritis Rheum; 2004 Feb; 50(2):565-9. PubMed ID: 14872500
[TBL] [Abstract][Full Text] [Related]
17. Anti-pm/scl antibodies in connective tissue disease: Clinical and biological assessment of 14 patients.
Vandergheynst F; Ocmant A; Sordet C; Humbel RL; Goetz J; Roufosse F; Cogan E; Sibilia J
Clin Exp Rheumatol; 2006; 24(2):129-33. PubMed ID: 16762146
[TBL] [Abstract][Full Text] [Related]
18. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD).
Bodolay E; Csiki Z; Szekanecz Z; Ben T; Kiss E; Zeher M; Szücs G; Dankó K; Szegedi G
Clin Exp Rheumatol; 2003; 21(3):313-20. PubMed ID: 12846049
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts.
Muro Y; Nakanishi H; Katsuno M; Kono M; Akiyama M
Clin Chim Acta; 2017 Sep; 472():1-4. PubMed ID: 28687351
[TBL] [Abstract][Full Text] [Related]
20. Atypical clinical presentation of a subset of patients with anti-RNA polymerase III--non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining.
Ceribelli A; Krzyszczak ME; Li Y; Ross SJ; Chan JY; Chan EK; Burlingame RW; Webb TT; Bubb MR; Sobel ES; Reeves WH; Satoh M
Arthritis Res Ther; 2011 Jul; 13(4):R119. PubMed ID: 21781293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
